NASDAQ:TRDA

Entrada Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy TRDA

*Your capital is at risk

$6.58

-0.0600 (-0.90%)

At Close: Jun 03, 2026

Entrada Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -52.38. In total, the insiders bought 1.27M and sold 1.2M TRDA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-52.38
● Buy	1.27M shares
● Sell	1.2M shares
41% Buy Activity Moderate Positive Correlation
Sell Signal High Confidence May 04, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -52.38. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 30, 2025 Sell	Common Stock S-Sale	5am Ventures V, L.p. 10 Percent Owner	10% Owner	18 578 Value: $126.6K
Jun 30, 2025 Sell	Common Stock S-Sale	Parmar Kush	Director	6 422 Value: $43.8K
Jun 30, 2025 Sell	Common Stock S-Sale	Parmar Kush	Director	18 578 Value: $126.6K
Jun 27, 2025 Sell	Common Stock S-Sale	Parmar Kush	Director	55 735 Value: $385.1K
Jun 27, 2025 Sell	Common Stock S-Sale	Parmar Kush	Director	19 265 Value: $133.1K
Jun 27, 2025 Sell	Common Stock S-Sale	5am Ventures V, L.p. 10 Percent Owner	10% Owner	55 735 Value: $385.1K
Jun 27, 2025 Sell	Common Stock S-Sale	5am Ventures V, L.p. 10 Percent Owner	10% Owner	19 265 Value: $133.1K
Jun 27, 2025 Sell	Common Stock S-Sale	5am Ventures V, L.p. 10 Percent Owner	10% Owner	19 265 Value: $133.1K
Jun 27, 2025 Sell	Common Stock S-Sale	5am Ventures V, L.p. 10 Percent Owner	10% Owner	55 735 Value: $385.1K
Jun 27, 2025 Sell	Common Stock S-Sale	Parmar Kush	Director	19 265 Value: $133.1K
Jun 27, 2025 Sell	Common Stock S-Sale	Parmar Kush	Director	55 735 Value: $385.1K
Jun 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Parmar Kush	Director	19 000 Value: $150.1K
Jun 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Kim Peter S Director	Director	19 000 Value: $150.1K
Jun 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Thistle Mary Director	Director	19 000 Value: $150.1K
Jun 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Zeiher Bernhardt G Director	Director	19 000 Value: $150.1K
Jun 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Chapman Gina Director	Director	19 000 Value: $150.1K
Jun 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Chapman Gina Director	Director	19 000 Value: $150.1K
Jun 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Zeiher Bernhardt G Director	Director	19 000 Value: $150.1K
Jun 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Thistle Mary Director	Director	19 000 Value: $150.1K
Jun 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Kim Peter S Director	Director	19 000 Value: $150.1K
Jun 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Parmar Kush	Director	19 000 Value: $150.1K
May 14, 2024 Buy	Common Stock P-Purchase	Kim Peter S Director	Director	25 000 Value: $364.7K
May 14, 2024 Buy	Common Stock P-Purchase	Kim Peter S Director	Director	25 000 Value: $364.7K
May 13, 2024 Buy	Common Stock P-Purchase	Kim Peter S Director	Director	25 000 Value: $367.0K
May 13, 2024 Buy	Common Stock P-Purchase	Kim Peter S Director	Director	25 000 Value: $367.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ENTRADA THERAPEUTICS, INC.

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also eng...

Read Full Profile Here